Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
3
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
9 treatments under study, led by Positron Emission Tomography
Research Leaders
6 sponsors active, led by National Cancer Institute (NCI)
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Research Network
Common Treatments
- Positron Emission Tomography2
- Epcoritamab2
- Biospecimen Collection2
- Computed Tomography2
- Lenalidomide1
Active Sponsors
- National Cancer Institute (NCI)3
- Children's Oncology Group1
- Genmab1
- Timothy Voorhees1
- Reem Karmali1
Top Investigators
Ohio State University Comprehensive Cancer Center
Children's Oncology Group
Northwestern University
Related Conditions
- Recurrent Monomorphic Posttransplant Lymphoproliferative Disorder2
- Ebvrelated Posttransplant Lymphoproliferative Disorder2
- Refractory Monomorphic Posttransplant Lymphoproliferative Disorder2
- Refractory Polymorphic Posttransplant Lymphoproliferative Disorder2
- Polymorphic Posttransplant Lymphoproliferative Disorder1